What “stage” means here
Cancer staging (I–IV, TNM, etc.) depends on tumour type. Roughly: Stage I often means early/localised disease; Stage II larger or more invasive local disease; Stage III typically locally advanced disease and/or regional lymph-node involvement. Exact definitions vary. Always use your pathology report and staging system.
Early / localised
Curative-intent SOC is primary. Research questions are usually about adjuncts, trials, and not delaying proven care.
Stage I page →Intermediate local
Often multimodal SOC (surgery ± chemo/RT/targeted/immuno). Investigational agents only with physician oversight.
Stage II page →Locally advanced / nodes
Higher complexity; coordinated oncology first. Combination trials and published dose ranges as facts only.
Stage III page →Core principles on every stage page
- Standard of care first. Surgery, radiotherapy, chemotherapy, immunotherapy and targeted therapy decided with your oncologist remain the backbone.
- Investigational = adjunct research interest. IVM / FBZ / MBZ in oncology are not approved cancer drugs. Discuss only as research context.
- No DIY dose orders. Where trial dose ranges appear, they are published study facts with links — not instructions to self-medicate.
- Lab monitoring and drug interactions belong in a clinical conversation (liver enzymes, concomitant chemo/ICI, QT, CYP, etc.).
- Search trials. Prefer formal studies: ClinicalTrials.gov and local registries.
Research anchors (all stages)
-
B Johns Hopkins / Gallia 2021 — MBZ phase I (HGG + TMZ)Dose-escalation safety with temozolomide; not a stage-III solid-tumour template.
-
A Patil 2022 — phase II recurrent GBMDifferent setting (recurrent high-grade glioma); missed internal OS target — include with positives.
-
A Egypt mCRC — MBZ + FOLFOX/bevacizumab (Hegazy / NCT03925662)Small single-centre signal in metastatic colorectal setting — not automatically transferable to every stage III cancer.
-
R IVM + ICI — TNBC (NCT05318469) · ICONIC (NCT07487805)Ongoing/early combination immunotherapy trials; check current status on ClinicalTrials.gov.
-
B Real-world IVM + MBZ observational (e.g. Hulscher 2026)Self-selected populations; high self-reported benefit is not the same as a controlled efficacy trial.
Questions worth taking to the oncologist
- What is my exact stage, subtype and planned SOC timeline?
- Are there open trials (including drug-repurposing arms) I qualify for?
- If I research antiparasitic agents, which interactions, liver/lab checks and red flags matter with my regimen?
- Who coordinates complementary or experimental questions on my team?